Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical

Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breached their fiduciary duties in connection with the proposed sale of the Company to Alcon (NYSE: ALC).

Background:

• On August 5, 2025, STAAR Surgical  and Alcon entered into a definitive merger agreement. Under the terms of the agreement, holders of STAAR Surgical’s common stock will receive $28.00 in cash for each share they own.
• Notably, this merger consideration falls well below STAAR Surgical’s 52-week high of $41.00 per share, even as Wall Street analysts continue to project accelerating sales and revenue growth for the company.

If you own STAAR Surgical shares and believe this proposed deal grossly undervalues your investment, please consider joining our investigation. To participate or learn more youcan click or copy and paste the following link to join this investigation:

If you are a shareholder of STAAR Surgical and interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.